192 related articles for article (PubMed ID: 37737691)
1. A Novel Type of IDH-wildtype Glioma Characterized by Gliomatosis Cerebri-like Growth Pattern, TERT Promoter Mutation, and Distinct Epigenetic Profile.
Muench A; Teichmann D; Spille D; Kuzman P; Perez E; May SA; Mueller WC; Kombos T; Nazari-Dehkordi S; Onken J; Vajkoczy P; Ntoulias G; Bettencourt C; von Deimling A; Paulus W; Heppner FL; Koch A; Capper D; Kaul D; Thomas C; Schweizer L
Am J Surg Pathol; 2023 Dec; 47(12):1364-1375. PubMed ID: 37737691
[TBL] [Abstract][Full Text] [Related]
2. Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases.
Kibe Y; Ohka F; Aoki K; Yamaguchi J; Motomura K; Ito E; Takeuchi K; Nagata Y; Ito S; Mizutani N; Shiba Y; Maeda S; Nishikawa T; Shimizu H; Saito R
Acta Neuropathol Commun; 2024 Apr; 12(1):57. PubMed ID: 38605367
[TBL] [Abstract][Full Text] [Related]
3. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.
Métais A; Tauziède-Espariat A; Garcia J; Appay R; Uro-Coste E; Meyronet D; Maurage CA; Vandenbos F; Rigau V; Chiforeanu DC; Pallud J; Senova S; Saffroy R; Colin C; Edjlali M; Varlet P; Figarella-Branger D;
Acta Neuropathol Commun; 2023 Jan; 11(1):14. PubMed ID: 36647073
[TBL] [Abstract][Full Text] [Related]
4. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
5. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
[TBL] [Abstract][Full Text] [Related]
9. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
[TBL] [Abstract][Full Text] [Related]
10. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
11. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
13. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
[No Abstract] [Full Text] [Related]
15. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
[TBL] [Abstract][Full Text] [Related]
17. Histone H3.3 G34-mutant Diffuse Gliomas in Adults.
Wang L; Shao L; Li H; Yao K; Duan Z; Zhi C; Song S; Cheng Y; Wang F; Wang W; Piao Y; Gui Q; Lu D; Qi X; Teng L
Am J Surg Pathol; 2022 Feb; 46(2):249-257. PubMed ID: 34352809
[TBL] [Abstract][Full Text] [Related]
18. TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis.
Hewer E; Phour J; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
J Neuropathol Exp Neurol; 2020 Apr; 79(4):430-436. PubMed ID: 32068851
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopathological and molecular genetic characteristics of adult IDH wild-type diffuse gliomas].
Wang LM; Wang W; Liu L; Gao M; Yao YY; Zhang M; Xiong YL; Shao Y; Lu DH; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):734-739. PubMed ID: 34405606
[No Abstract] [Full Text] [Related]
20. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
